OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.
about
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaComplementation of the Yeast Model System Reveals that Caenorhabditis elegans OCT-1 Is a Functional Transporter of AnthracyclinesSelecting the best frontline treatment in chronic myeloid leukemiaIncreased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.The pharmacogenetics of imanitib.SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsPredicting the response of CML patients to tyrosine kinase inhibitor therapy.Evolution of therapies for chronic myelogenous leukemia.OCT1 and imatinib transport in CML: is it clinically relevant?Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.OCT-1 as a determinant of response to antileukemic treatment.
P2860
Q26781539-D2DBEFC1-42CC-4874-9F7B-B884BDB65321Q28546572-FE29FDD0-362A-45F8-97AB-08ABB1FC7C55Q33764253-5BEE66C5-AFD1-421C-A557-17BA68785BD3Q33815980-A065D732-B54A-4034-934B-1F912071668BQ34469295-ECDF3B38-8250-45AE-96AA-AD7A5A17ED4FQ34525644-1F9118CB-B053-4E4E-AD25-593AA1BD8C24Q35708124-92E9195D-6DB8-471C-9944-668D3D881976Q36006408-1497AF31-0160-443B-BFF7-15388F4474F9Q37381574-0ED5767E-97D0-4A01-BD72-50577570585FQ37859303-3A7EC73E-F830-45FD-9E8C-53D18CD62C05Q37966915-33EC2ADF-0719-4AB2-9145-F8CE55181583Q38540022-44A56480-FD70-4CC4-9143-A614447501CDQ38622785-447F0169-580C-4834-AEF7-D37C0EA6256BQ38826494-2F841A1C-C390-42D8-8D34-AD5980A84DAFQ38843265-D80B1047-ADA7-4AED-9238-043BF91C9753Q49833785-B0901312-6C74-4999-9E89-357C7E7D7914Q53083526-D64C4334-8604-497D-AEBE-DFC01672724FQ54240000-FEA47B61-4743-4173-B0D7-9DB2EE37CF07Q54610682-C2C9212A-7FBE-4117-BCC1-DE59A736D00D
P2860
OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
OCT-1 activity measurement pro ...... eotide polymorphisms of OCT-1.
@en
OCT-1 activity measurement pro ...... eotide polymorphisms of OCT-1.
@nl
type
label
OCT-1 activity measurement pro ...... eotide polymorphisms of OCT-1.
@en
OCT-1 activity measurement pro ...... eotide polymorphisms of OCT-1.
@nl
prefLabel
OCT-1 activity measurement pro ...... eotide polymorphisms of OCT-1.
@en
OCT-1 activity measurement pro ...... eotide polymorphisms of OCT-1.
@nl
P2093
P2860
P356
P1433
P1476
OCT-1 activity measurement pro ...... eotide polymorphisms of OCT-1.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2010.188
P577
2010-09-02T00:00:00Z
P6179
1031735878